The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Impact of allo-HSCT on survival outcomes in accelerated/blast-phase MPN
|
A multicenter analysis that evaluated the survival outcomes associated with first-line treatment, response, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with accelerated/blast-phase myeloproliferative neoplasms (MPN-AP/BP) has been published in Blood Advances by Patel et al.1 |
| Key learnings1 |
|
Across 9 academic centers, the three most common first-line treatments for adult patients with MPN-AP/BP were intensive chemotherapy (IC), DNA methyltransferase inhibitor (DNMTi)-based regimens, and DNMTi combined with venetoclax (VEN). |
|
The median overall survival (OS) for patients with MPN-AP/BP was 0.86 years, regardless of first-line treatment. |
|
The median OS for patients who underwent allo-HSCT was 2.3 years from the time of transplant. |
|
These data highlight an unmet need in treating MPN-AP/BP, suggesting that current therapies provide limited survival benefits in the absence of allo-HSCT. |
|
There is a need for further research and development of more effective treatments for patients who are ineligible for or unable to receive allo-HSCT. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
